Dharminder Chahal

Supervisory Director

Dharminder Chahal is owner and managing director of Exponential B.V. in which capacity he acts as consultant to Van Herk Investments and companies in the Van Herk Investments portfolio. Furthermore he is CEO and co-founder of SkylineDx a company based in Rotterdam, The Netherlands, and developing diagnostic tests in oncology. Mr. Chahal has built an extensive network in the global life science industry and created a strong track record in supporting successful companies in their journeys, a.o. Crucell sold to Johnson and Johnson, deVGen sold to Syngenta and Ablynx sold to Sanofi. Currently the main investments in the portfolio are Galapagos, Zealand Pharma (Denmark) and BioInvent (Sweden). As a board member or advisor he has been and still is active for several European companies and funds in the field of life sciences. In addition to his board membership at Medis, Mr. Chahal is Chairman of the Board of DCPrime, Sensara and Anemones Hospitality and Hotels (India), Board member of BioInvent (Sweden), VitalneXt and Ceradis and he is Observer of the Board at Bio2 Technologies (US), Miach Orthopaedics (US) and VBHC (India). Mr. Chahal previously held various positions in investment banking and asset management, including Kempen & Co and Robeco. Mr. Chahal obtained a master degree in Business Economics (Erasmus University Rotterdam) and a master degree cum laude in Aerospace Engineering (TU Delft).